Core Viewpoint - Huahai Pharmaceutical reported a significant decline in both revenue and net profit for H1 2025, primarily due to falling product prices and increased R&D investments [1][2] Financial Performance - H1 revenue reached 4.516 billion yuan, a year-on-year decrease of 11.93% [1] - Net profit attributable to shareholders was 409 million yuan, down 45.30% year-on-year [1] - Non-recurring net profit was 363 million yuan, a decline of 52.48% compared to the previous year [1] - Operating cash flow for H1 was 370 million yuan, a drop of 71.52% year-on-year [2] Reasons for Decline - The decline in net profit is attributed to three main factors: 1. Continuous price drops due to intensified competition and domestic procurement policies, despite an increase in market share [1] 2. Accelerated R&D investments in biological innovation drugs [1] 3. Decreased foreign exchange gains due to currency fluctuations [1] R&D Progress - The product HB0034 (Ruxolitinib injection) has been prioritized for review by the National Medical Products Administration (NMPA) and is expected to be approved for market in Q2 2026 [3] - The key III phase clinical trial for HB0017 for moderate to severe plaque psoriasis is nearing completion, while the trial for ankylosing spondylitis is ongoing [3] - In the oncology pipeline, HB0025 for advanced or recurrent endometrial cancer has submitted a meeting request for confirmatory III phase clinical trials, and significant efficacy data for non-small cell lung cancer will be presented in early September [3]

Core Points - The company held its fourth temporary board meeting of the ninth session on August 25, 2025, with all nine directors present, meeting the legal quorum requirements [1] - The board approved the 2025 semi-annual report and its summary, with a unanimous vote of 9 in favor [2] - The board also approved a special report on the use of raised funds for the first half of 2025, again with a unanimous vote [2] - A resolution was passed for the company's subsidiaries to apply for a total credit limit of up to 1.623 billion yuan from banks, with a maximum term of 5 years [2][3] - The board authorized the management team to handle all credit-related procedures within the approved limit without needing further board approval [3] - The board approved a guarantee for a subsidiary, Zhejiang Huahai Jiancheng Pharmaceutical Co., Ltd., for a bank credit limit of up to 205 million yuan [3][5] - The authorization for the guarantee is valid for one year from the date of board approval [3][5]

证券日报网讯 8月25日晚间，华海药业发布公告称，公司于2025年8月25日召开第九届董事会第四次临 时会议，审议通过了《关于公司为下属子公司提供担保议案》，同意公司为下属子公司华海建诚向银行 申请授信额度提供合计不超过2.05亿元（最终以实际发生额为准）的信用担保。 （文章来源：证券日报） ...

Core Viewpoint - Huahai Pharmaceutical (600521) reported a decline in both revenue and net profit for the first half of 2025, primarily due to intensified domestic procurement policies, increased competition in the raw material pharmaceutical industry, and the impact of US-China tariffs [1] Financial Performance - The company achieved an operating revenue of 4.516 billion yuan, a year-on-year decrease of 11.93% [1] - The net profit attributable to shareholders was 409 million yuan, reflecting a year-on-year decline of 45.3% [1] Market Conditions - Despite an increase in market share for major products, continuous price declines negatively impacted sales revenue and profit [1] - The company is accelerating the progress of its biopharmaceutical innovation projects, resulting in a significant year-on-year increase in R&D investment [1] - Foreign exchange rate fluctuations contributed to a decrease in exchange gains compared to the previous year [1]

Group 1 - Company announced a credit guarantee of up to 205 million yuan for its wholly-owned subsidiary Huahai Jiancheng to meet funding needs [1] - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to approximately 3.572 billion yuan, which is 40.15% of the latest audited equity attributable to shareholders [1] - The breakdown of guarantees includes approximately 3.105 billion yuan for subsidiaries (34.89% of the latest audited equity) and 263 million yuan for associated companies (2.95% of the latest audited equity) [1] Group 2 - For the year 2024, the revenue composition of Huahai Pharmaceutical is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - The current market capitalization of Huahai Pharmaceutical is 34 billion yuan [2]

为进一步优化资金配置，提高财务运营效率，满足下属子公司生产经营和业 务发展需要，公司下属子公司拟向银行申请授信额度（或融资额度）总计不超过 人民币 16.23 亿元（最终以实际发生额为准），授信期限最长不超过 5 年。以上授 信额度不等于公司实际融资金额，具体融资金额将根据运营资金的实际需求确定， 并最终以银行实际审批的授信额度为准。授信有效期内，授信额度可循环使用且 可以在不同银行间进行调剂。为提高工作效率，及时办理融资业务，董事会授权 公司经营管理层或经营管理层转授权相关人士在上述综合授信额度内全权办理授 信相关手续，包括签署相关法律文件等，具体实施事宜无须再另行提交公司董事 会审议。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）于 2025 年 8 月 25 日召开第九届董事会第四次临时会议，审议通过了《关于公司下属子公司 向银行申请综合授信额度的议案》，现将相关事项公告如下： | 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2 ...

| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2025-094 号 | | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | 为满足公司下属全资子公司华海建诚在业务发展及建设过程中的资金需求， 公司于 2025 年 8 月 25 日召开第九届董事会第四次临时会议，审议通过了《关于 公司为下属子公司提供担保议案》，同意公司为下属子公司华海建诚向银行申请授 信额度提供合计不超过 2.05 亿元（最终以实际发生额为准）的信用担保。具体情 况如下： 浙江华海药业股份有限公司 关于为子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、担保情况概述 （一）基本情况概述 1 / 4 单位：人民币亿元 担保 方 被担保方 担保方持 股比例 被担保方最 近一期资产 负债率 截至目 前担保 余额 本次新 增担保 额度 新增担保额度占上 市公司最近一期归 属于上市公司股东 的所有者权益的比 担保有 效期 是否关 联担 ...

（一）2020 年公开发行可转换公司债券 经中国证券监督管理委员会证监许可〔2020〕2261 号文核准，并经上海证券交易 所同意，浙江华海药业股份有限公司（以下简称"公司"或"华海药业"）由主承销 商浙商证券股份有限公司（以下简称"浙商证券"）采用向原股东优先配售，原股东 优先配售后余额部分（含原股东放弃优先配售部分）通过网上向社会公众投资者发售 的方式，向社会公开发行可转换公司债券（以下简称"可转债"）1,842.60 万张，每 张面值为人民币 100 元，按面值发行，共募集资金 184,260.00 万元，扣除承销和保荐 费（未包括已预付的 141.51 万元）1,596.79 万元后的募集资金为 182,663.21 万元， 已由主承销商浙商证券于 2020 年 11 月 6 日汇入本公司募集资金监管账户。另减除预 付保荐费、律师费、验资费、资信评级费和发行手续费等与可转债直接相关的外部费 用 492.76 万元后，公司本次募集资金净额为 182,170.45 万元。上述募集资金到位情 况业经天健会计师事务所（特殊普通合伙）（以下简称"天健"）验证，并由其出具 《验资报告》（天健验〔2020〕479 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第九届董事会第四次临时会议于 二零二五年八月二十五日上午九点在公司四楼会议室以通讯方式召开。会议应到会 董事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司董事 长李宏先生主持。会议程序符合《中华人民共和国公司法》（以下简称"公司法"）、 《中华人民共和国证券法》（以下简称"《证券法》"）及《浙江华海药业股份有限公 司章程》（以下简称"公司章程"）的规定。会议审议并通过了如下决议： 一、审议通过了《公司 2025 年半年度报告全文及其摘要》 表决情况：同意：9 票；反对：0 票；弃权：0 票。 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2025-091 号 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 第九届董事会第四次临时会议决议公告 该议案已经公司第九届董事会审计委员会第三次会议审议 ...

Financial Performance - The company's operating revenue for the first half of 2025 was CNY 4,516,353,788.97, representing a decrease of 11.93% compared to the same period last year[21]. - Total profit for the first half of 2025 was CNY 542,860,973.47, down 43.24% year-on-year[21]. - Net profit attributable to shareholders of the listed company was CNY 409,487,616.19, a decline of 45.30% compared to the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 363,424,637.01, which is a decrease of 52.48% year-on-year[23]. - The net cash flow from operating activities was CNY 369,637,712.53, down 71.52% compared to the same period last year[23]. - Basic earnings per share decreased by 46.15% to CNY 0.28 compared to the same period last year[24]. - The company reported a net profit of CNY 405.16 million, a decline of 46.36% from CNY 754.35 million in the first half of 2024[174]. - The company's total comprehensive income for the first half of 2025 was CNY 819,445,641.77, down from CNY 1,252,422,802.32 in the previous year[178]. Assets and Liabilities - Total assets reached CNY 21,265,898,469.48, reflecting a growth of 4.96% from the end of the previous year[23]. - The company's total liabilities amounted to approximately CNY 11.261 billion, with current liabilities around CNY 5.699 billion and non-current liabilities approximately CNY 5.561 billion[161]. - The company's total current assets reached CNY 8.899 billion as of June 30, 2025, compared to CNY 8.483 billion at the end of 2024[165]. - The company's long-term borrowings stood at CNY 2,518,092,895.00, representing 11.84% of total liabilities, with a slight increase of 0.26% compared to the previous year[82]. - The company's total equity increased to CNY 13.95 billion, up 11.19% from CNY 12.55 billion year-over-year[173]. Research and Development - The company accelerated the R&D of biopharmaceutical innovation projects, resulting in a substantial increase in R&D expenses compared to the previous year[24]. - R&D investment totaled CNY 64.88 million, accounting for 14.36% of revenue, with a year-on-year increase of 23.07%[50]. - The company is focusing on developing innovative drugs in the fields of autoimmune diseases and oncology, with over 70 domestic and international patents filed[32]. - The company is leveraging AI technology to enhance R&D processes and improve the speed and efficiency of drug development[57]. - The company is advancing its innovative drug pipeline, particularly in next-generation antibody-drug conjugates and tumor immunotherapy, to meet unmet clinical needs[58]. Market and Sales Strategy - The company has established a production model based on sales forecasts, ensuring timely delivery of orders while maintaining reasonable inventory levels[35]. - The company has implemented a multi-channel sales strategy, enhancing its domestic and international market reach through various sales models[40]. - The company is actively pursuing international expansion, particularly in the U.S. market, by diversifying its supply chain and enhancing operational management[55]. - The company’s sales network covers over 100 countries and regions, with a market share of nearly 90% among major clients[30]. - The domestic formulation business is strategically focusing on market penetration and expanding into new markets despite price pressures from centralized procurement[53]. Quality Management and Compliance - The company has a comprehensive quality management system recognized by major international certifications, ensuring compliance with cGMP and EHS standards[42]. - The company emphasizes quality management, adhering to strict quality standards and regulations to ensure product excellence throughout its lifecycle[74]. - The company is committed to quality management and EHS, enhancing its compliance and safety management systems[64]. - The company is enhancing its quality management system to align with international standards and address increased regulatory scrutiny post-COVID-19[95]. Corporate Governance and Management - The company has undergone significant changes in its board and senior management, with new appointments made for key positions[106]. - The company has not proposed any profit distribution or capital reserve transfer plans for the current period[107]. - There are no reported instances of non-operating fund occupation by controlling shareholders or related parties[7]. - The company has committed to not engage in any competitive business activities during the period of being the actual controller, ensuring no direct or indirect participation in businesses that compete with the company's products[111]. Financial Management and Investments - The total amount of guarantees provided by the company, including those to subsidiaries, is 1,936,670,266.37 RMB, which accounts for 19.54% of the company's net assets[122]. - The company made a new equity investment of ¥30,000,000.00 in Beijing Saifu Pharmaceutical Research Institute, holding a 1.4113% stake[84]. - The company has invested 75,150,000.00 RMB in wealth management products during the period, increasing the total value of these products to 75,309,980.78 RMB[86]. - The company has established a vertically integrated supply chain from raw materials to formulations, enhancing its competitive edge in both generic and innovative drugs[67]. Industry Challenges and Outlook - The pharmaceutical industry is characterized by high technology, high investment, and high risk, with increasing competition and regulatory challenges[45]. - The domestic pharmaceutical industry is facing intensified competition, with a projected revenue of approximately 297.63 billion yuan in 2024, remaining flat year-on-year[47]. - The company faces risks from price volatility in raw materials due to intensified competition and geopolitical uncertainties[99]. - The company is closely monitoring exchange rate fluctuations, as its overseas business primarily settles in USD, which may impact revenue and profit levels[100].